Corporate digest
Trendlines Group
CATALIST-LISTED Trendlines Group, the Israel-based group which focuses on early-stage, high growth innovation-based medical and agricultural technologies, has signed a definitive agreement to sell its BioSight Ltd shares to Arkin Bio Ventures Limited Partnership that will bring it pre-tax proceeds of about US$1.3 million.
"BioSight developed a technology and pipeline of cancer drugs that target and release therapeutic drugs inside cancer cells to reduce systemic toxicity associated with conventional chemotherapy treatments," Trendlines said.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
HCA beats first-quarter profit estimates on higher patient admissions
F&B operator YKGI to exclusively operate Chicha San Chen in Macau for next eight years
LMIRT Q1 net property income dips 3.1% to S$30 million on higher expenses
Exxon misses on Q1 profit despite big gains in Guyana
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
Chevron's quarterly profit beats estimates